MAP2K7 and neoplasm: Furthermore, we demonstrate that therapy with a mitogen-activated protein kinase (MEK) inhibitor U0126 causes a transient decrease in tumor glycolytic activity, consistent with downregulation of signal transduction downstream MEK, but does not significantly affect the rate of tumor growth.